Warsaw Genomics

What Warsaw Genomics does

Warsaw Genomics S.A. is a private Polish genetic diagnostics company headquartered on the University of Warsaw campus that operates its own NGS laboratory and provides genetic testing services directly to patients and physicians. The company runs a dual go-to-market: a self-serve direct-to-consumer online portal where Polish patients can order panels without a physician referral, complemented by a dedicated physician portal (Strefa Lekarza) that enables clinicians to order, track, and access genetic results for their patients. The company monetizes through one-time per-panel fees, with pricing ranging from roughly 1,450 PLN (~$360) for single-gene tests to 9,094 PLN (~$2,250) for trio whole-exome sequencing, plus separately billed medical consultations. Revenue from the Poradnia clinic (genetic counseling, endocrinology, targeted oncology therapies, e-prescriptions) provides an additional recurring clinical service stream.

The core technology stack is Illumina-based next-generation sequencing combined with in-house bioinformatics (Burrows-Wheeler Aligner) and variant interpretation following ACMG/AMP guidelines. The company's principal technical differentiator is a proprietary reference database of approximately 100,000 Polish genomes used to interpret variants more accurately for Polish patients than reliance on global public databases (gnomAD, ClinVar, OMIM) alone. The portfolio spans 333+ panels covering oncology, rare diseases, cardiovascular, neurological, metabolic, endocrine, sensory, renal, and pharmacogenetic conditions, plus whole-exome sequencing (WES for one or three persons), single-gene tests, Signatera ctDNA-based MRD monitoring, the newly launched ATARAXIS cancer risk assessment product, and somatic profiling for pancreatic cancer. Quality is validated through CAP, EMQN, QCMD, and Instand certifications.

The company operates exclusively in the Polish market, serving individual patients, a wide range of physician specialists (geneticists, oncologists, endocrinologists, cardiologists, neurologists, GPs), and pursuing public-health-scale screening through the Badamy Geny (We Examine Genes) population program. An interdisciplinary team of 30 doctors, diagnosticians, bioinformaticians, and scientists — affiliated with University of Warsaw and Warsaw Medical University — supports both clinical service delivery and R&D. Cumulatively, the laboratory reports 600,000+ diagnostic tests performed (including SARS-CoV-2) and 6,000+ genetic and endocrinology consultations, with a standard 23-day turnaround time.

Name

Warsaw Genomics

Legal name

Warsaw Genomics S.A.

Website

https://warsawgenomics.pl

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Warsaw Genomics is a Polish genetic diagnostics company operating its own NGS laboratory and offering 333+ genetic test panels, whole-exome sequencing, and pharmacogenetics directly to patients and physicians in Poland. It differentiates through a proprietary reference database of ~100,000 Polish genomes used for population-specific variant interpretation.

Ownership category

akta.pro rank

Product category

Clinical Genetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Public Health Genomics & Sequencing (WGS/Metagenomics) Networks (HLAJAIAK)

Keywords

• Clinical genetic diagnostics
• Next-generation sequencing
• Pharmacogenetics testing
• Exome sequencing services
• Molecular diagnostics

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genetic Testing Services: The company sells individual genetic tests and panels to patients (directly) and physicians (via the physician portal). Tests are priced per panel and include sample collection (at home kit or collection point), laboratory analysis (NGS sequencing and in-house interpretation), and online result delivery. Medical consultation is offered as a separate service.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Warsaw Genomics operates a clinical genetics laboratory in Warsaw, Poland, performing next-generation sequencing (NGS)-based genetic tests including 333+ diagnostic panels, whole-exome sequencing (WES), single-gene tests, and pharmacogenetic panels. Tests are interpreted in-house using a proprietary database of approximately 100,000 Polish genomes and offered both directly to consumers via an online patient portal and to physicians via a dedicated physician channel.

Product overview

Warsaw Genomics is a genetic diagnostics company offering a comprehensive portfolio of genetic testing products and services based on next-generation sequencing (NGS) technology. The core offering consists of diagnostic panels organized by health areas (oncology, nervous system, cardiovascular, metabolism, rare diseases), whole exome sequencing (WES), and single gene analysis. The product portfolio includes specialized offerings such as Signatera™ for circulating tumor DNA (ctDNA) monitoring and ATARAXIS for cancer risk assessment. Services are complemented by a medical clinic providing genetic counseling, endocrinology consultations, and targeted oncology therapies. The company also operates the 'Program Badamy Geny' population screening initiative aimed at testing the entire Polish population. The business model allows patients to order tests directly without referral, with sample collection at dedicated points and results delivered online with medical consultation.

Differentiator

Problem solved

Functional benefit

Products and services

• Diagnostic genetic panels (Panele diagnostyczne) A menu of 333+ targeted NGS-based genetic panels covering hereditary cancer, cardiovascular, metabolic, neurological, and other disease areas; available via the patient portal and physician channel for clinicians and self-paying patients.
• Whole-exome sequencing (WES / Badanie całoeksomowe) Clinical WES and trio-WES analysis for patients with suspected rare genetic disorders; performed and interpreted in-house.
• Single-gene tests (Pojedyncze geny) Individual gene testing for specific mutations where targeted analysis is sufficient and cost-effective.
• Pharmacogenetics panels Pharmacogenetic testing panels to predict drug response and help clinicians optimize medication selection and dosing.
• Signatera (ctDNA molecular residual disease monitoring) Tumor-informed circulating tumor DNA test used for molecular residual disease detection and recurrence monitoring in oncology patients.
• ATARAXIS Specialized genetic testing offering within the Warsaw Genomics portfolio, positioned for risk assessment and personalized prevention.
• Somatic profiling — pancreatic cancer Tumor profiling test for pancreatic cancer designed to identify actionable somatic mutations to guide treatment decisions.
• Genetic counseling clinic (Poradnia) In-person and remote genetic consultation services staffed by clinical geneticists to help patients interpret results and decide on next steps.
• Program Badamy Geny (We Test Genes screening program) Population-level genetic screening initiative designed to broaden access to genetic testing for Polish residents.

Quantifiable outcome

• 600,000+ diagnostic tests performed (including SARS-CoV-2)
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core.

• University of WarsawcoreStrategic or Co-development PartnerWarsaw Genomics is closely affiliated with the University of Warsaw, with its interdisciplinary team of doctors and scientists drawn from the university. The company is housed in the Centre of New Technologies Building (CNBCH) at the university campus, reflecting deep academic collaboration in research and development of genetic diagnostics.
• Warsaw Medical University (Warszawski Uniwersytet Medyczny)coreStrategic or Co-development PartnerThe interdisciplinary team of 30 doctors and scientists includes specialists from Warsaw Medical University, combining clinical and academic expertise to advance genetic diagnostics and interpretation.
• IlluminacoreTechnology or IntegrationAll genetic testing is performed using Illumina next-generation sequencers. Illumina is the core technology partner providing the sequencing platform that underpins all of Warsaw Genomics' diagnostic services.
• ClinVar (NCBI)coreTechnology or IntegrationWarsaw Genomics uses ClinVar, the NIH-supported public database of genetic variants, as a reference resource for variant interpretation alongside its own proprietary database.
• gnomAD (Broad Institute)coreTechnology or IntegrationThe gnomAD population frequency database from the Broad Institute is used as a reference for assessing variant pathogenicity in genetic test interpretation.
• OMIM (Online Mendelian Inheritance in Man)coreTechnology or IntegrationOMIM, the comprehensive database of human genetic disorders and genes, is used as a reference for linking variants to disease phenotypes in test interpretation.
• ACMG/AMP Standards (American College of Medical Genetics and Genomics / Association for Molecular Pathology)coreTechnology or IntegrationWarsaw Genomics classifies genetic variants according to ACMG/AMP guidelines, the internationally recognized standard for variant pathogenicity classification in clinical genetics.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Dante Labs: Italy-based direct-to-consumer whole-genome and whole-exome sequencing provider with online ordering and physician-ordered channels. Closely comparable D2C genetic testing motion, NGS technology stack, and panel breadth, though with a different geographic focus.
• Centogene: Germany-based clinical genomics laboratory offering rare disease diagnostics, NGS panels, and pharmacogenetics with multi-country physician and patient channels. Directly comparable on business model (clinical lab + physician portal) and product portfolio (panel-based genetic testing) to Warsaw Genomics, with broader European reach.
• Natera: US-based clinical genomics company whose Signatera circulating tumor DNA test for MRD monitoring is offered by Warsaw Genomics under partnership. Comparable on clinical NGS oncology testing and ctDNA technology, and the most direct comparable for Warsaw's Signatera distribution line.
• Color: US-based clinical genetics company offering hereditary cancer, pharmacogenomics, and population genomics with employer-sponsored and physician channels. Comparable on dual D2C/clinical model, panel-based offering, and integration of consultation services.
• Blueprint Genetics: Clinical genomics laboratory specializing in NGS panels for hereditary disease, including rare disease and oncology panels with physician-channel distribution. Closely comparable on test menu breadth, clinical-grade NGS focus, and quality certification footprint.

Regional players

• ALAB Laboratoria: Polish network of medical diagnostics laboratories offering a wide menu of clinical tests including genetic diagnostics. Comparable on Poland-based clinical lab operations, B2B physician channel, and DTC sample collection infrastructure, though with a broader non-genetic test focus.
• Medicover Genetics: Genetics offering within the Medicover healthcare group operating in Poland and other Central European markets. Direct regional peer operating private healthcare and diagnostics channels in Poland, comparable customer base and country context, though embedded within a larger healthcare provider.

Broad incumbents

• PerkinElmer Genomics: Genomics services arm of PerkinElmer offering clinical NGS panels for rare disease, newborn screening, and oncology. Comparable on clinical-grade NGS panels and population genomics capabilities, embedded in a much larger life sciences instrumentation and services business.
• Eurofins Genomics: Division of Eurofins Scientific offering a broad portfolio of genomic services including NGS, Sanger sequencing, and pharmacogenetics across Europe. Overlaps with Warsaw Genomics on sequencing services and panel offerings but operates as part of a much larger diversified testing platform.
• Invitae: US-based clinical genetic testing company offering a broad NGS-based test menu across hereditary cancer, rare disease, reproductive health, and pharmacogenetics with both physician and patient channels. Comparable on product breadth and clinical NGS positioning, though materially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/warsawgenomics
• Facebookfacebook.com/WarsawGenomics
• LinkedInlinkedin.com/company/warsaw-genomics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Warsaw Genomics